ZyVersa Therapeutics
ZyVersa is committed to developing biopharmaceuticals that address unmet medical needs of patients wi
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases. Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kid
In a recent interview on Benzinga All Access, our CEO Stephen Glover described the significant unmet need and market opportunity in kidney disease, and how ZyVersa’s Cholesterol Efflux Mediator™ VAR 200 has the potential to improve kidney function and reduce kidney disease progression. Watch it here: https://bit.ly/3RziWFN
ZyVersa Therapeutics | Stephen C. Glover | Benzinga All Access Check out www.benzinga.com for complete coverage along with all the latest financial news and data!Follow us Online!📸Instagram: www.instagram.com/benzinga👍...
Our CEO, Stephen Glover, addressed the 2024 outlook for ZyVersa and the biotechnology industry in a recent interview on Benzinga All Access. For more information: https://bit.ly/4aNDAL1
In an interview on the Big Biz Show, our CEO Stephen Glover discussed ZyVersa's two lead drug candidates, Cholesterol Efflux Mediator™ VAR 200 for chronic kidney diseases and Inflammasome ASC Inhibitor IC 100 for inflammatory diseases and their key 2024 development milestones. Watch the interview: https://bit.ly/4aMOgtc
BBS 01 04 24 Steve Glover ZyVersa Update on Key 2024 Milestones.
ICYMI ZyVersa's CEO Stephen Glover issued a letter to shareholders providing an outlook for 2024, read it here: https://bit.ly/41HnRJp
ZyVersa announces that Noble Capital Markets has initiated company-sponsored equity research coverage. To obtain a copy of the full report authored by Noble Capital Markets’ Senior Research Analyst Robert LeBoyer, as well as news and advanced market data on ZyVersa Therapeutics, please go to Channelchek.com. https://bit.ly/48AADfv
ZyVersa announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a Letter to Shareholders providing a corporate outlook with anticipated milestones for 2024. Read the full letter here: https://bit.ly/41HnRJp
Attending BIO Partnering @ JPM being held January 8-12, 2024? To schedule a meeting with ZyVersa's CEO Stephen Glover, please sign up in the conference portal or contact Karen Cashmere, Chief Commercial Officer at [email protected]. https://bit.ly/3GLxddc
Our CEO Stephen Glover spoke with Benzinga All Access about ZyVersa's two lead products, Cholesterol Efflux Mediator™ VAR 200 for chronic kidney diseases and Inflammasome ASC Inhibitor IC 100 for inflammatory diseases, as well as upcoming catalysts. Watch the full interview here: https://bit.ly/3RziWFN
ZyVersa Therapeutics | Stephen C. Glover | Benzinga All Access Check out www.benzinga.com for complete coverage along with all the latest financial news and data!Follow us Online!📸Instagram: www.instagram.com/benzinga👍...
Our CEO Stephen Glover will hold one-on-one meetings with pharmaceutical companies and investors to discuss ZyVersa’s business and clinical development strategy, recent corporate achievements, and anticipated milestones during the BIO Partnering @ JPM event. For more info: https://bit.ly/3tlHXMw
Our CEO Mr. Stephen Glover was featured on the Big Biz Show to speak about ZyVersa's work to develop products to meet the high unmet medical needs for inflammatory and kidney diseases, and share his thoughts on the macroeconomic environment for the biotech segment in 2024. Watch the interview: https://bit.ly/3GTlZn7
The Big Biz Show, Interview with ZyVersa CEO Stephen Glover Mr. Glover discusses ZyVersa's products in development for inflammatory and renal diseases, and provides his thoughts on the macroeconomic environment for th...
Tune-in today, December 20th at 11am ET for ZyVersa CEO Stephen Glover's interview with Benzinga All Access: https://bit.ly/3GPaqgH
Live Trading With Benzinga + All Access | December 20, 2023 On LIVE Trading with Benzinga, Daytrading, Options, Penny Stocks, & Blue Cap Stocks every weekday morning from 9am-11am ET.Check Out Our New Partnership With...
Tune-in to Benzinga All Access on Wednesday, December 20th at 11am ET for an interview with our CEO Stephen Glover to learn about ZyVersa's two lead products, Cholesterol Efflux Mediator™ VAR 200 for chronic kidney diseases and Inflammasome ASC Inhibitor IC 100 for inflammatory diseases. https://bit.ly/3Rug2BT
ZyVersa announces that Stephen Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in BIO Partnering @ JPM being held January 8-12, 2024 in San Francisco. For details: https://bit.ly/3tlHXMw
Cholesterol Efflux Mediator VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to chronic kidney disease and its progression. Learn more: [link] [PR Graphic]
Our CEO Stephen Glover comments on engaging CRO George Clinical to manage ZyVersa's Phase 2a clinical trial of Cholesterol Efflux Mediator VAR 200 in patients with diabetic Kidney disease (DKD). Read more: https://bit.ly/3RHGZn2
ZyVersa announces selection of contract research organization George Clinical to manage its Phase 2a clinical trial with Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease (DKD). The clinical trial is expected to begin in the first quarter of 2024. For details: https://bit.ly/3RHGZn2
The article published in Alternative Therapies demonstrates that plasma NLRP3 inflammasomes and their resulting proinflammatory cytokines are significantly elevated in early-stage diabetic kidney disease and that levels progressively increase as kidney function worsens. For key findings, visit: https://bit.ly/3NdqcWr
Our CEO Stephen Glover comments on research published in the peer-reviewed journal, Alternative Therapies, which suggest that early diabetic kidney disease intervention with inflammasome inhibitors has potential to attenuate disease progression. Learn more: https://bit.ly/3Ngsowr
ZyVersa announces publication of an article in the peer-reviewed journal, Alternative Therapies, demonstrating that plasma levels of NLRP3 inflammasomes correlate with progression of diabetic kidney disease (DKD) in patients with Type 2 diabetes. For details: https://investors.zyversa.com/news-releases/news-release-details/zyversa-therapeutics-announces-publication-demonstrating-plasma
ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which inhibits multiple inflammasome pathways (including NLRP3 and AIM2) to attenuate initiation and perpetuation of damaging inflammation that is pathogenic in numerous diseases. Learn more: https://bit.ly/483rPxT
Our CEO Stephen Glover comments on research published in the peer-reviewed journal, Diabetes, which supports IC 100’s rationale for targeting ASC to inhibit multiple inflammasome pathways. Learn more: https://bit.ly/483rPxT
ZyVersa announces publication of an article in the peer-reviewed journal, Diabetes, demonstrating that AIM2 and NLRP3 inflammasome activation contributes to development of atherosclerosis in two different animal models of type 1 diabetes. For details: https://bit.ly/483rPxT
Our CEO Stephen Glover comments on research published in Biomedical Journal that provides support for inflammasome inhibition as a promising treatment option for inflammatory bowel disease (IBD). Learn more: https://bit.ly/46mPU1z
ZyVersa announces publication of an article in the peer-reviewed Biomedical Journal demonstrating that inhibiting NLRP3 inflammasomes in an IBD animal model attenuates intestinal inflammation and tissue damage, leading to significant improvements in IBD symptoms, and restoration of normal intestinal microbial flora. For key findings: https://bit.ly/46mPU1z
ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which can inhibit up to 12 different inflammasomes (including NLRP3 inflammasomes) and their associated ASC specks which perpetuate damaging inflammation. To review a white paper summarizing the mechanism of action and preclinical data for IC 100, please visit: https://bit.ly/3Pn5FR2
Our CEO Stephen Glover comments on research published in Ecotoxicology and Environmental Safety that provides support for inflammasome inhibition as a promising treatment option for kidney disease. For key findings: https://bit.ly/3QLhAsd
ZyVersa announces publication of an article in the peer-reviewed journal, Ecotoxicology and Environmental Safety, linking air pollution with development and progression of chronic kidney disease that can be attenuated by inhibiting inflammasome NLRP3 activation. Learn more: https://bit.ly/3QLhAsd
The Molecular Neurobiology paper reinforces published data demonstrating that Inflammasome ASC Inhibitor IC 100 attenuates the inflammatory response causing neuronal damage in a multiple sclerosis model, potentially providing neuroprotection. For key findings: https://bit.ly/3FHOyDw
Our CEO Stephen Glover comments on research published in the peer-reviewed journal, Molecular Neurobiology, which provides support for Inflammasome ASC Inhibitor IC 100 as a potential therapeutic option for multiple sclerosis. To read the paper on IC 100 in an animal model of MS: https://bit.ly/3QmpjLT
ZyVersa announces a publication in the peer-reviewed journal, Molecular Neurobiology, demonstrating neuroprotective effects of NLRP3 inflammasome inhibition in a mouse model of multiple sclerosis using a research tool molecule, MCC950. Learn more: https://bit.ly/3FHOyDw
Click here to claim your Sponsored Listing.
Videos (show all)
Category
Telephone
Website
Address
2200 N. Commerce Parkway, Suite 208
Weston, FL
33326
1820 N Corporate Lakes Boulevard Suite 303
Weston, 33326
Somos tu socio estratégico que comercializar y distribuir tus productos en Estados Unidos y España.
Weston, 33326
We have over 18 years of experience in all aspects of Manufacturing, Product Design, Product Development, Business Development, and Worldwide Fulfillment. Whether you partner with ...
2700 Glades Circle Suite 160
Weston, 33327
Innovative #ideas that transform empty #spaces into habitable spaces. Making our #client grow 🎯
5365 N Hiatus Road
Weston, 33331
We are the premier builders of swimming pools and complete outdoor remodels in South Florida.
FL , EE. UU.
Weston, 33327
� Leading Company in the Construction . � Ex*****on of Projects and Works . � Business consolidation . � Home improvement . � Home remodeling .